About Ignota Labs
Ignota Labs is an AI-driven drug turnaround company that re-engineers promising but failing drugs, unlocking value in shelved programmes. Its proprietary SAFEPATH platform combines deep learning, cheminformatics, bioinformatics, and multimodal data to uncover the root causes of drug toxicity and deliver actionable insights to revive distressed pharmaceutical assets.
Company details
Funding
Total raised
$6.9M
Last stage
Seed
Investors
Founders
Sam Windsor
Previously part of the consulting team shaping commercialisation strategy for Google DeepMind's AlphaFold. Has a decade of experience in life sciences. Holds an MBA from INSEAD (Dean's List, top 10%).
LinkedInLayla Hosseini-Gerami
PhD in cheminformatics/bioinformatics from the University of Cambridge (Andreas Bender's group). Expert in AI and cheminformatics. Won the Chemistry Theory Outstanding Thesis Award in 2023.
Jordan Lane
PhD focused on Alzheimer's Disease from the University of Nottingham. Has advanced five assets to clinical development. Previously at AstraZeneca, LabGenius, and BenevolentAI.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.